

AMENDMENT TO THE SPECIFICATION

Please replace the paragraph beginning at page 1, line 5, with the following rewritten paragraph:

This application is a continuation of U.S. Patent Application Serial Number 09/189,193, filed November 9, 1998, now U.S. Patent Number 6,184,359, which is a continuation of U.S. Patent Application Serial Number 08/725,969, filed October 4, 1996, which is a divisional of U.S. Patent Application Serial Number 08/393,305, filed February 22, 1996, which is a continuation-in-part of co-pending U.S. Patent Application Serial Number 08/233,606, filed April 22, 1994, which is a continuation-in-part of co-pending U.S. Patent Application Serial Number 08/031,399 filed March 8, 1993.

Please replace the paragraph beginning at page 10, line 22, with the following rewritten paragraph:

The present invention also comprises other mammalian ETF, including human ETF, having ETF biological activity and encoded by nucleotide sequences that hybridize, under conditions of moderate to high stringency, to probes defined by SEQ ID NO:1, SEQ ID NO:4, and SEQ ID NO:12. A plasmid containing a recombinant clone of human EFT cDNA was deposited with the American Type Culture Collection, ATCC, 10801 University Boulevard, Manassas, VA 20110-2209 in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of the Patent Procedure on February 19, 1993 under accession number ATCC 69245. The deposit was named "I41-hETF" and comprised an *E. coli* strain containing plasmid hETF/pDC that contained a 316-bp 5' noncoding region preceding an open reading from of 486 bp and a 400-bp 3' noncoding region flanked by the *Sal* I adapters shown in SEQ ID NOS:7 and 8. All restrictions on the availability to the public of the material deposited will be irrevocably removed upon the granting of a patent.